Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases

Dayun Feng1#, Mengmeng Wang2#, Jie Hu3#, Songlun Li4, Shoujie Zhao5, Huichen Li6, Lei Liu7

1Department of surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China; 2Department of Drug and Equipment, Aeromedicine Identification and Training Centre of Air Force, Xi'an 710069, China; 3Department of Clinical laboratory, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China; 4Department of Blood Transfusion, Tangdu Hospital, The Fourth Military Medical University, Xi'an, 710038, China; 5Department of General Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China; 6The State Key Laboratory of Cancer Biology, Department of Biochemistry and Molecular Biology, School of Basic Medicine, Fourth Military Medical University, Xi'an 710032, China; 7Department of Gastroenterology, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China

Contributions: (I) Conception and design: L Liu; (II) Administrative support: H Li; (III) Provision of study materials or patients: S Li; (IV) Collection and assembly of data: S Zhao; (V) Data analysis and interpretation: D Feng, M Wang, J Hu; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors contributed equally to this work.

Correspondence to: Lei Liu, MD, PhD. Department of Gastroenterology, Tangdu Hospital of the Fourth Military Medical University, No. 569 Xinsi Road, Xi'an 710038, China. Email: tdlulei@fmmu.edu.cn.

Abstract: One of the most commonly used systems for grading liver function in hepatocellular carcinoma (HCC) patients is the Child-Pugh (CP) score. However, the CP scoring system is not without its shortcomings: for example, the cut-off values for the parameters are calculated arbitrarily and the assessment of ascites and hepatic encephalopathy is subjective. More recently, an alternative to traditional CP grade has emerged in the form of albumin-bilirubin (ALBI) grade. The predictive value provided for HCC patients by the ALBI grade is comparable to that of the CP grade; however, it can also surpass CP grade by greatly reducing subjectivity and further subdividing CP A patients into several different groups, thus improving the prognosis judgment and helping to inform clinicians' optimal decision-making. The application of the ALBI grade into currently used HCC staging systems such as the Barcelona Clinic Liver Cancer (BCLC) staging system, the Cancer of the Liver Italian Program (CLIP) staging system, and the Japan Integrated Staging (JIS) score, etc., as well as newly produced systems like the ALBI-PLT grade, the ALBI and progression disease (ALBI-PD) grade and Modified Intermediate Stage of Liver Cancer (MICAN) criteria, greatly elevates prognostic power.

Keywords: Hepatocellular carcinoma (HCC); liver diseases; Child-Pugh score (CP score); albumin-bilirubin grade; prognostic value

Submitted Nov 29, 2019. Accepted for publication Jan 15, 2020.
doi: 10.21037/atm.2020.02.116

View this article at: http://dx.doi.org/10.21037/atm.2020.02.116

Introduction

Hepatocellular carcinoma (HCC) is considered as the fifth most common cancer and the third main cause of cancer-related deaths (1,2). The prognoses of HCC patients remain bleak, even though there have been significant advancements in surgical techniques, liver transplantation, local-regional treatments, and molecular target therapy (3). Owing to the interplay of tumor development and liver function, the complexity in managing HCC is dramatically increased. Clinical practice and outcomes are both significantly influenced by the underlying liver dysfunction, as well as by the stage and extent of the tumor itself (4).

For liver function assessment, the Child-Pugh (CP)
score is used by most of the international guidelines for the management of HCC. Furthermore, CP score is adopted into inclusion and exclusion criteria in the majority of clinical trials for HCC (5-10). The CP score is calculated from five variables: three liver function tests (total bilirubin, albumin and prothrombin time); and two based on clinical symptoms (ascites and hepatic encephalopathy). However, as essential as the conventional CP classification is for the assessment of liver function, its imperfections introduce a number of limitations.

Firstly, the CP score was originally developed, using an empirical rather than evidence-based method, for assessing the prognoses of patients affected by cirrhosis and portal hypertension who undergo surgical treatment for variceal bleeding (11,12). In this sense, CP score is more suitable to be applied in cirrhotic rather than non-cirrhotic patients. Clinically, however, it is clear that, of HCC patients, a significant proportion have a non-cirrhotic background (13,14). According to reports, there was no histological evidence of cirrhosis in almost half of patients who undergo surgical resection of HCC (15). Secondly, it includes subjective factors evaluating the presence of ascites and encephalopathy. A consensus on how to determine the severity of these symptoms is yet to be agreed. For example, the grade of the severity of ascites may depend on a physician's experience. Furthermore, ascites may also be affected by the diuretic or by the tumor itself. An equal amount of difficulty may be encountered when grading encephalopathy, as many of its early symptoms resemble those of the HCC itself. Thirdly, laboratory variables, which include albumin, bilirubin and prothrombin time have their cut-off points calculated arbitrarily. Fourthly, there is close interrelation between some of the indexes in the CP class, including ascites and serum albumin. Fifthly, as most HCC patients were found to be CP A at diagnosis, it has been suggested that for the assessment of liver function, CP score shows a relative lack of granularity (16).

With regard to the limitations of CP score outlined above, the albumin-bilirubin (ALBI) grade, a novel nomogram of liver function assessment sorely based on serum albumin and total bilirubin, has recently been proposed as an alternative for HCC patients (16). The ALBI grade can objectively stratify HCC patients into three risk groups and predict significantly different overall survival (OS) during follow-up. In comparison with CP score, it has three main advantages. Firstly, it was established through an evidence-based process especially for the assessment of liver function in HCC patients, and—in both non-cirrhotic and cirrhotic populations—performs adequately. Secondly, as it solely uses the criteria of serum albumin and total bilirubin, it is a simple and objective method of assessment which removes the need for subjective clinical variables and makes the classification between observers more reliable. Thirdly, it has a higher granularity than CP score for assessing liver function because it can stratify CP A patients according to different survival outcomes (17).

The prognostic value of ALBI grade in HCC after different therapies

Many studies have validated the ALBI grade’s prognostic power in different therapies and HCC staging systems (Table 1). Baseline ALBI grade has been shown in many studies to be a powerful prognostic factor for OS, no matter what the therapeutic option is (4,18-25). Furthermore, with an increase of ALBI grade, the OS of patients becomes significantly worse. In the study by Kuo et al., the OS for ALBI grades 1, 2 and 3 after sorafenib therapy significantly decreased from 14.8 months, to 5 and 0.7 months, respectively (18). Similarly, in the study by Pinato et al., the survival outcomes of ALBI grade 1, 2 and 3 were 13, 6.3 and 1.6 months, respectively (19). In addition, the hazard ratio (HR) between ALBI 2 and 1 was 1.7 (95% CI: 1.1–2.9) and between ALBI 3 and ALBI 1 was 4.1 (95% CI: 2.5–6.8). In the study by Kuo et al., those with increased ALBI grade had significantly poorer survival than those with non-changed ALBI grade after sorafenib treatment (2.1 vs. 6.4 months, P<0.001) (18).

Association of ALBI grade and BCLC stage

As the Barcelona Clinic Liver Cancer (BCLC) staging system is one of the most commonly used HCC staging systems, the prognostic power of the ALBI grade across each of the BCLC stages has been the focus of a large number of studies.

Using a stage-stratified approach, Pinato et al. investigated the ALBI grade’s prognostic ability in both curative and palliative groups and proved it has sufficient and clinically significant stratifying power across all of the BCLC stages of HCC (17). In early-stage HCC, they confirmed that the ALBI grade could distinguish those with poorer prognosis within CP A class patients, who are generally regarded as candidates for surgical resection (26). Li et al. (4) confirmed that there can be increased survival outcomes for patients undergoing resection at ALBI grade.
<table>
<thead>
<tr>
<th>Items</th>
<th>Study</th>
<th>Type of study</th>
<th>Characters of patients</th>
<th>No. pts</th>
<th>HR (95% CI); P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ALBI 2 vs. 1</td>
</tr>
<tr>
<td>OS &amp; baseline ALBI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sorafenib</td>
<td>Kuo et al. [2017] (18)</td>
<td>Single-center, retrospective</td>
<td>BCLC C, C-P A, with MVI or with EHM</td>
<td>260</td>
<td>2.35 (1.43–3.87); P&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Pinato et al. [2017] (19)</td>
<td>Multi-center, retrospective</td>
<td>61% BCLC C</td>
<td>378</td>
<td>1.61 (1.21–2.14); P&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Edeline et al. [2016] (20)</td>
<td>Multi-center, retrospective</td>
<td>78.1% BCLC C, 70.9% C-P A</td>
<td>1,019</td>
<td>1.68 (1.43–1.97); P&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Lee et al. [2017] (21)</td>
<td>Single-center, retrospective</td>
<td>BCLC C, C-P A</td>
<td>404</td>
<td>1.869 (1.474–2.370); P&lt;0.001</td>
</tr>
<tr>
<td>SBRT</td>
<td>Toesca et al. [2017] (22)</td>
<td>Single-center, retrospective</td>
<td>N/A</td>
<td>40</td>
<td>P=0.86</td>
</tr>
<tr>
<td>Resection</td>
<td>Ma et al. [2016] (23)</td>
<td>Multi-center, retrospective</td>
<td>BCLC 0-A, 95.6% C-P A</td>
<td>Cohort 1, 160</td>
<td>2.586 (1.516–4.412); P=0.000</td>
</tr>
<tr>
<td></td>
<td>Pinato et al. [2017] (19)</td>
<td>Single-center, retrospective</td>
<td>65% BCLC A</td>
<td>581</td>
<td>3.474 (2.152–5.585); P&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Li et al. [2017] (4)</td>
<td>Single-center, retrospective</td>
<td>C-P A</td>
<td>491</td>
<td>1.394 (1.146–1.696); P=0.001</td>
</tr>
<tr>
<td></td>
<td>Toyoda et al. [2016] (24)</td>
<td>Multi-center, retrospective</td>
<td>C-P A</td>
<td>Japan cohort: 536</td>
<td>1.9 (1.5–2.5); P&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hong Kong cohort: 450</td>
<td>2.4 (1.6–3.7); P&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Europe cohort: 162</td>
<td>1.7 (1.0–2.9); P=0.05</td>
</tr>
<tr>
<td>RFA</td>
<td>Toyoda et al. [2016] (24)</td>
<td>Multi-center, retrospective</td>
<td>–</td>
<td>Japan cohort: 267</td>
<td>1.7 (1.1–2.6); P=0.024</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hong Kong cohort: 275</td>
<td>1.7 (1.1–2.4); P=0.003</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Europe cohort: 162</td>
<td>2.0 (1.3–3.0); P=0.002</td>
</tr>
<tr>
<td>TACE</td>
<td>Pinato et al. [2017] (19)</td>
<td>Multi-center, retrospective</td>
<td>95.2% BCLC 0-A, 85.7% C-P A</td>
<td>622</td>
<td>2.975 (2.104–4.206); P&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Kao et al. [2017] (25)</td>
<td>Single-center, retrospective</td>
<td>USA cohort, 86% BCLC B</td>
<td>315</td>
<td>1.16 (0.83–1.63); P=0.12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Europe cohort, 73% BCLC B</td>
<td>423</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Asia cohort, 91% BCLC B</td>
<td>723</td>
</tr>
<tr>
<td>PST &amp; post-treatment ALBI</td>
<td>Sorafenib</td>
<td>Pinato et al. [2017] (19)</td>
<td>Multi-center, prospectively</td>
<td>62% BCLC C, 75% C-P A</td>
<td>386</td>
</tr>
<tr>
<td></td>
<td>Lee et al. [2018] (21)</td>
<td>Single-center, retrospective</td>
<td>BCLC C, C-P A, PD</td>
<td>310</td>
<td>2.023 (1.213–3.373); P=0.007</td>
</tr>
<tr>
<td>SBRT</td>
<td>Toesca et al. [2017] (22)</td>
<td>Single-center, retrospective</td>
<td>–</td>
<td>40</td>
<td>2.7; P=0.002</td>
</tr>
<tr>
<td>OS &amp; ALBI change (increase)</td>
<td>Sorafenib</td>
<td>Kuo et al. [2017] (18)</td>
<td>Single-center, retrospective</td>
<td>BCLC C, C-P A, with MVI or with EHM</td>
<td>260</td>
</tr>
<tr>
<td></td>
<td>SBRT</td>
<td>Toesca et al. [2017] (22)</td>
<td>Single-center, retrospective</td>
<td>–</td>
<td>40</td>
</tr>
</tbody>
</table>

ALBI, albumin-bilirubin grade; Pts, patients; OS, overall survival; MVI, macro-vascular invasion; EHM, hepatic metastasis; PD, progression disease; SBRT, stereotactic body radiation therapy.
1 in comparison with those at ALBI grade 2 in the BCLC stage 0-A (68 vs. 52 months, P=0.004) and stage B (26 vs. 20 months, P=0.044). In intermediate-stage HCC, it was reported that the ALBI grade was an accurate predictor of survival for patients treated with transcatheater arterial chemoembolization (TACE) in three geographically distinct patient cohorts (the USA, Europe, and Asia cohorts). In advanced HCC, the study showed that, in addition to its ability to predict survival independently, the ALBI grade outperformed CP in identifying patients with a higher risk of early mortality before sorafenib initiation.

**Incorporating ALBI grade into different HCC staging systems**

A patient’s clinical stage is the principal factor in the clinical management of their HCC. In addition to the BCLC staging system, there have been several other clinical staging systems proposed for HCC, including the American Joint Committee on Cancer (AJCC) staging system, the Okuda classification, the Cancer of the Liver Italian Program (CLIP), and the Japan Integrated Staging (JIS) score (27-31). However, the ability of current ongoing staging systems to accurately predict prognoses and inform guiding treatment selection remains inadequate. For example, a significant proportion of BCLC patients, particularly those in East Asia, undergo hepatectomy, which BCLC guidelines recommend for patients at BCLC stage 0-A (32). Many BCLC stage A and C patients also receive TACE therapy, which BCLC guidelines recommend for BCLC stage B patients. This phenomenon may be largely connected with inaccurate assessment of liver function.

The newly established ALBI grade has been incorporated into some of the HCC staging systems and has successfully replaced the original liver function evaluation method used in HCC staging systems, producing a better prognostic power according to homogeneity likelihood Chi-Square, C-Index, and corrected Akaike information criterion (AIC). Chan et al.’s study explored the prognostic ability of the CP-based BCLC system in comparison with the ALBI-based BCLC system and demonstrated a similar overall prognostic performance between the two systems with regard to homogeneity, discriminatory ability, and the monotonicity of gradients (33). Shao et al.’s study proved ALBI-CLIP had higher R and lower AIC than CLIP, demonstrating ALBI-CLIP might perform better than CLIP did in predicting prognosis (34).

There were two studies that compared the prognostic ability of the CP-based JIS score with that of the ALBI-based JIS score (ALBI-T score) (35,36). The results of these studies also indicated that the ALBI-T score performed better than the CP-based JIS score in predicting prognosis. A further two studies that compared the prognostic performances of JIS score, liver damage base JIS score (modified JIS score) and ALBI-T score. In the study by Hiraoka et al., AIC results showed that the prognostic performance of the ALBI-T score was better than modified JIS score and JIS score (37).

**Prognostic comparison of ALBI grade and CP class**

The comparisons between the prognostic values of ALBI grade and CP class are shown in Table 2. Although some studies which only compared one of the indexes were not shown in the table, most studies showed ALBI grade to have better discriminatory abilities than CP score. In contrast with most other studies, Edeline et al. (20) found that ALBI grade shared a similar prognostic power with CP score for CP A group (AICs: 6,649 vs. 6,652, P=0.02, Harrel’s C-Index: 0.56 vs. 0.57), although CP score showed better discriminatory ability for patients overall (AICs: 8,876 vs. 8,898, P<0.001). For trials of systemic therapy, their findings placed CP class A within the included criteria but found ALBI to be only a stratification indicator. There were also studies comparing ALBI grade with liver damage grade (LD), which is a more effective indicator than CP score for patients with early-stage HCC (38). Hiraoka et al. demonstrated that despite LD slightly outperforming ALBI grade in terms of AIC value for patients with early-stage HCC who received RFA, the median survival time for each individual ALBI grade exceeded that of the corresponding LD (39).

**ALBI grade in CP class A patients**

CP A patients are usually considered candidates for a variety of HCC treatments. For example, CP A class patients are generally regarded as ideal candidates for surgical resection (26). International guidelines suggest that TACE should be limited to those with CP A disease. Current guidelines and prospective trials restrict the use of stereotactic body radiation therapy (SBRT) to patients with CP class A cirrhosis (40-42) due to concerns regarding liver tolerance to radiation. Previous studies
usually applied CP class A or B as their eligibility criteria (6,7,17,18,20,21). However, it is recognized that, within this single grade, there is a wide variation in hepatic function (43-45). Of the studies included in Table 3, many showed ALBI to improve the accuracy of prognoses, especially within the CP A group (46). These studies demonstrated that although patients were all classified as CP A, their prognoses still varied a lot, and they could be sub-classified into different grades according to ALBI grade with significantly different survival outcomes. Due to the disadvantages of CP score and the advantages of ALBI grade previously mentioned, as well as the obvious survival heterogeneity within CP A, ALBI grade may be more suitable than CP score as one of the inclusion criteria in relation to liver function assessment in HCC patients. No comparisons of the subclassifications by points [5–15] within the CP classification were included in the original study. Some studies compared the prognostic power of ALBI 1/2 and CP 5/6. Most of them determined that ALBI 1/2 had a superior differentiating efficacy for prognoses than C-P 5/6 within the Child Pugh (CP) A class.

**Refinement of ALBI grade: ALBI 2A and 2B**

Although ALBI grade has been proved to improve prognostic power, there remain some drawbacks. Some studies have suggested a potentially higher prognostic heterogeneity in grade 2 patients. For example, Pinato et al. found that, while 92% of patients in ALBI grade 1 met the criteria of CP A, the percentage of patients in ALBI grades 2 and 3 who satisfied the criteria was lower (73% and 3% of ALBI grade 2 and 3, respectively) (18). Similarly, in Ogasawara et al.’s study, the majority of patients with ALBI grade 1 had a CP score of 5, in contrast with patients with ALBI grade 2, who had a wide range of liver reserve according to the CP score, with scores of 5, 6, 7, and ≥8 (47). ALBI grade 2 patients were divided into two groups, ALBI grade 2A and 2B, according to the median ALBI 2 score (grade 2A, ≤–2.118 and grade 2B, ≥2.118). Unlike most studies, the results demonstrated that there was no significant difference in prognosis for ALBI grades 1 and 2, while prognosis of ALBI grade 2B group was significantly worse than that of the ALBI grade 1 group (P=0.029) and of the 2A group (P=0.004). According to the multivariate survival analyses, the risk of death was particularly higher in ALBI grade 2B group (HR, 2.265; 95 % CI, 1.021–5.022; P=0.044). Thus, it was suggested that the subdivision of patients with ALBI grade 2 could increase the efficiency of ALBI in distinguishing the prognoses of patients receiving sorafenib treatment, which may be suitable for patients who are in the advanced stages of HCC and ALBI grade 1, and for some with ALBI grade 2 (notably ALBI 2A). Considering the small number of studies on the subdivision of ALBI 2, more studies

### Table 2 Prognostic comparison between ALBI grade and Child-Pugh class

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Study</th>
<th>No. pts</th>
<th>AUROC (95% CI)</th>
<th>AICs</th>
<th>Harrel’s C-Index</th>
<th>Homo χ²</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>ALBI grade</td>
<td>CP class</td>
<td>P value</td>
<td>ALBI grade</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>Pinato et al. [2017] (19)</td>
<td>386</td>
<td>0.69</td>
<td>0.66</td>
<td>&lt;0.001</td>
<td>0.64</td>
</tr>
<tr>
<td></td>
<td>Edeline et al. [2016] (20)</td>
<td>All patients [905]</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>8,898</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CP A patients [722]</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>6,652</td>
</tr>
<tr>
<td></td>
<td>Lee et al. [2018] (21)</td>
<td>404</td>
<td>0.709</td>
<td>0.756</td>
<td></td>
<td>1,899.94</td>
</tr>
<tr>
<td>Resection</td>
<td>Li et al. [2017] (4)</td>
<td>491</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>4,768.84</td>
</tr>
<tr>
<td>RFA</td>
<td>Kao et al. [2017] (25)</td>
<td>622</td>
<td>2,006.709</td>
<td>2,160.717</td>
<td></td>
<td>54.01225.155</td>
</tr>
</tbody>
</table>

ALBI, Albumin-bilirubin grade; CP, Child-Pugh.
are required to validate these results.

**Other systems based on ALBI grade**

**MICAN**

BCLC guidelines recommend TACE to intermediate-stage HCC patients (48). However, hepatic function, as well as tumor size and number beyond Milan criteria (multinodular HCC without macrovascular invasion or extrahepatic metastasis) all inform the prognoses of intermediate-stage HCC patients (38,42,49-53). Based on clinical manifestation, Japanese clinical practice guidelines recommend a variety of therapies, such as surgical resection (hepatectomy) and TACE, for intermediate-stage HCC patients (54-57). Recently, a Japanese study (58) proposed a new sub-staging method, called Modified Intermediate Stage of Liver Cancer (MICAN) criteria, which predicts intermediate-stage patients’ prognoses and informs their treatment using the ALBI grade. Four sub-stages were defined by ALBI grade and up-to-7 criteria: ALBI-1/within up-to-7 criteria (B1), ALBI-2/within up-to-7 criteria (B2), ALBI-1 and ALBI-2/multiple and beyond up-to-7 criteria (B3), and ALBI-3/any (B4) (31). The median survival time for those classified as B1, B2, B3, and B4 was 65.1, 48.1, 29.6, and 14.6 months, respectively (P<0.01 for each comparison). As the MICAN stage increased, the availability of curative treatments like hepatectomy and RFA decreased, while the availability of palliative treatments like TACE and sorafenib increased. For instance, 67.0% of those in the B1 sub-stage underwent hepatectomy and received RFA, with the percentages of those in the B2, B3 and B4 sub-stages receiving the same treatments falling to 51.4%, 28.3% and 12.1%, respectively. The study also compared MICAN criteria with other evaluation systems which use subclassification to inform prognoses, such as Bolondi’s criteria and Kinki criteria and concluded that the result of the AIC for the MICAN criteria was superior to those of Bolondi’s and the Kinki criteria (990.5, 993.0 and 1,001.4, respectively) (59,60). The study confirmed that MICAN criteria based on ALBI grade can be applied for predicting survival and guiding therapies in the heterogeneous population of BCLC-B patients (58).

**Platelet-bilirubin-albumin grade**

Although the ALBI grade has been widely validated, it fails to incorporate portal hypertension. The platelet-bilirubin-albumin (PALBI) grade, which incorporates the blood platelet count as a surrogate marker for portal hypertension, was produced through additional modifications to the ALBI grade (61). Liu et al.’s study found there to be a significant difference in survival across all of the ALBI and PALBI grades (62). Both grades could predict survival across various HCC
stages, yet the PALBI grade’s AUC was significantly higher than the ALBI grade’s at 1, 3, and 5 years. Based on current studies, more research is required to determine whether or not the PALBI grade has better prognostic power than the ALBI grade.

**ALBI grade and progression disease patterns**

Those advanced-stage HCC patients who had failed first-line therapy but who had better liver reserves were potentially eligible for second-line clinical trials (62,63). Earlier second-line trials typically included CP class A or B7 in their eligibility criteria (64-68). However, as previously mentioned, there is heterogeneity in survival outcomes for CP A patients.

Lee et al. further proposed the novel ALBI grade and progression disease (ALBI-PD) criteria for second-line trials (21). The study considered ALBI grade 3 at PD, new extrahepatic lesions (NEH), and early PD within 4 months to be independent predictors of poor post-progression survival, and these were then incorporated into the ALBI-PD criteria. Of the patients in this study classified as having CP A liver function at PD, those who met the ALBI-PD criteria had significantly longer median PPS than patients who were beyond it. Furthermore, for those with CP A5 to B7 status, ALBI-PD criteria could significantly discriminate the PPS. They also compared the ALBI-PD criteria with the ALBI grade and conventional CP class. According to ROC analysis, ALBI-PD score better predicted post-progression mortality at 6, 9, and 12 months. The ALBI-PD criteria also performed well with regard to having the lowest AIC value and highest homogeneity (presented by Wald $\chi^2$ value).

**ALBI grade in other liver diseases**

Due to the accurate discriminative power of the ALBI grade in liver function evaluation, several studies have validated the performance of the ALBI grade in other liver diseases besides HCC.

Toesca et al. demonstrated a correlation between baseline ALBI grade ($P=0.02$) and post-treatment ALBI (HR: 2.9, $P=0.013$) and a worse OS time in cholangiocarcinoma patients treated with SBRT (22). In relation to patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure, Chen and Lin confirmed the prognostic ability of the ALBI score in predicting 3-month outcomes (69). Chen et al. demonstrated the higher accuracy of the ALBI score—in comparison to the CP and model for end-stage liver disease (MELD) scores—when used to predict long-term prognoses for patients with HBV-related cirrhosis (70). Chan et al. confirmed that ALBI grade was an independent factor in predicting the prognoses of patients with primary biliary cirrhosis and, when compared to alternative prognostic evaluation systems, gave a better or comparable performance (71).

**Conclusions**

Overall, the ALBI grade’s significant superiority in HCC and other liver diseases has been recognized. Many studies have confirmed that baseline ALBI grade is an important prognostic factor for OS. However, more studies are needed to evaluate the prognostic value of post-treatment ALBI grade and changes in ALBI grade. In addition, there is still some debate surrounding the superiority of ALBI grade over the conventional CP score. More high-level evidence is required to investigate this issue and to assist in establishing better HCC staging systems based on ALBI grade.

**Acknowledgments**

**Funding:** This work was supported by the National Natural Science Foundation of China (81702999), the Innovation Capability Support Program of Shaanxi province (2018KJXX-076) and the Health and Family Planning Commission of Shaanxi province (2017SF-208) for LL.

**Footnote**

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.02.116). LL serves as the unpaid editorial board member of Annals of Translational Medicine from Apr 2020 to Mar 2022. The other authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References
25. Kao WY, Su CW, Chiou YY, et al. Hepatocellular Carcinoma: Nomograms Based on the Albumin-Bilirubin Grade to Assess the Outcomes of Radiofrequency


49. Reig M, Darnell A, Forner A, et al. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the


